@ShawnBinda Your father was always so humble for all he accomplished with Devi Mandir. Memories of Sunday service, yajnas & Shivraatri celebrations in the original “house”will always be dear to me. You continuing in his footsteps is the best tribute to his memory. Best wishes this Diwali 🪔
Four important studies from #ESMO26 today:
1. Endometrial cancer (Lancet): Sacituzumab tirumotecan (TROP2-targeted ADC) improved median overall survival from 12.1 to 19 months after prior chemotherapy and immunotherapy.
2. dMMR endometrial cancer (Lancet): First-line pembrolizumab alone improved median PFS (time without progression) from 8.4 to 38.2 months vs chemotherapy alone. A promising chemo-free option, although chemo plus immunotherapy remains the current standard.
3. Osteosarcoma (ARTEMIS-011): Risvutatug rezetecan (B7-H3-targeted ADC) improved median PFS from 1.4 to 5.5 months vs chemotherapy in heavily pretreated patients, including adolescents. A rare positive phase 3 trial in this disease.
4. An important caution (MOIO): In patients whose advanced cancer was responding after 6 months of immunotherapy, extending treatment intervals to every 12 weeks was unexpectedly associated with higher observed mortality (19.9% vs 10.5%) compared with standard dosing. The phase 3 trial was stopped early.
Important advances, but also a reminder that less treatment is not always better.
#UCSFMHP2026: Sam Brondfield (@s_brond) on what hospitalists need to know about inpatient oncology. Nice graphic of types of cancer Rx (along with risk of immunosuppression for each), and another with overall prognosis of patients with metastatic cancers of various types.
Kicking off the 30th (!) annual @UCSF Management of the Hospitalized Patient conference, with 500 attendees here in SF. I'll tweet 1-2 key points for each talk for the next few days at #UCSFMHP2026.
🧵 1/10 The arc: POLAR - MDF – TIE
Pancreatic cancer is profoundly resistant to immune checkpoint inhibitors.
Yet, POLAR (pembrolizumab plus olaparib) trial showed that a subset of patients, especially with HRD (gBRCA2/1m or gPALB2m) tumors, can achieve remarkably durable control.
That led us to two questions:
#1 👆🏼what makes these tumors immunogenic?
#2 ✌️what makes that immunity actually work?
👑 #2. POLAR TIE @biorxivpreprint
https://t.co/IAQpmSzBE0
#1. MDF https://t.co/9vqCZF8Z6i
#0. POLAR @NatureMedicine https://t.co/UtCD1C7i4R
#cancer #immunotherapy #PancreaticCancer #ICI #BRCA #HRD #3episodes @MSKCancerCenter@MSK_DeptOfMed@CpcrMsk@ldiaz1971@debschrag@PanCAN@oncodaily@OncoDailyGI@OncoAlert@OncBrothers@brunolarvol
🚨 The @FDA has granted “Breakthrough Therapy” designation to FMISO, a specialized imaging tracer that can help identify patients with #HPV-positive #throatcancer who may safely receive less-intensive radiation treatment.
“This has been an absolute game changer for treating certain people with throat cancers caused by the human papillomavirus or HPV,” says MSK radiation oncologist @imrtlee, who pioneered the approach.
Learn more: https://t.co/Z1TGukvCcY
Four areas of opportunity highlighted in @theNCI
FY2028 Annual Plan:
-Advancing Functional Precision Medicine
-Expanding the Reach of Cell-based Immunotherapies
-Fully Utilizing Pediatric Cancer Data
-Leveraging Tumor Atlases to Predict Cancer’s Evolution
https://t.co/bjlDlhAuKF
Top Outfield, Infield, and Firstbase Velocities from the 2026 PG WWBA Workout Showcase (July 5th) in Marietta, GA.
Check out the full Workout Results here: https://t.co/J6jLYuQhU8
@PGShowcases@PerfectGameUSA
Top 10 Yard Splits and 60 Yard Dash Times from the 2026 PG WWBA Workout Showcase (July 5th) in Marietta, GA.
Check out the full Workout Results here: https://t.co/J6jLYuQhU8
@PGShowcases@PerfectGameUSA
SS/RHP Rohan Persad
2027, @TorontoMets@PB_Uncommitted
Persad drills this one into the LCF gap for a triple.
The two-way out of the Met’s system collects his second hit this game.
#NYSGames || @RoShowBaseball
SS/RHP Rohan Persad
2027, @TorontoMets@PB_Uncommitted
Persad laces this one thru the right-side for a backside single.
Two-way out of the Mets’ system w/ a fastball the reaches the mid-80s.
#NYSGames || @RoShowBaseball
Happy Father’s Day to all the dads spending “their” day driving to baseball diamonds & the like. we see you and appreciate everything you do everyday for the ones who made you the dads you are. Missing the dads and grand-pas who left us way too early 💔
Great job this weekend @RoShowBaseball keep working hard 💪 we’re very proud of how far you’ve come & looking forward to more great baseball ⚾️ @TorontoMets
"Grateful, but I don't like any of it."
I asked Bassitt about the standing ovation he got from the Blue Jays' crowd yesterday. Covering Cbass for his years in Toronto, I know he doesn't like a fuss made about him, but if you don't, Bassit hates getting attention:
@6ixinningpod